BNT116 lung-cancer vaccine remains under study in first-in-human trial

Evidence stage: Early HumanRegulatory status: InvestigationalGuideline status: Not addressed

BNT116, an investigational NSCLC (non-small-cell lung cancer) vaccine, is under study in the LuCa-MERIT-1 first-in-human trial. Trial registry: https://clinicaltrials.gov/study/NCT05142189. The registry describes the trial as first-in-human and recruiting, with multiple treatment cohorts, as of the current source record — the cohorts must not be reduced to a single universal regimen in any summary. This is a Phase I, investigational, ongoing clinical trial: no efficacy claim is made or should be made here, since no primary posted trial result was supplied by the governing directive. This story is primarily ABOUT an ongoing trial, not about a proven result. [Identifiers as supplied, attributed to independent verification outside this environment — not independently re-verified live here.]

What This Means

An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities, treatment-emergent adverse events) and dose.

What This Doesn't Mean

This is not evidence the vaccine works — no primary efficacy result exists to report, and no study results have been posted to the registry; any preliminary efficacy signal in this trial is secondary/exploratory only.

Why It Matters

Represents continued investment in therapeutic cancer vaccines for one of the most common and lethal cancers; worth tracking as the trial progresses.

Promise & Proof

Proof — strength of the evidence 2 / 5
  • Base score from evidence stage: Early Human.
Promise — potential significance if later evidence holds up 4 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • Targets a cancer type with historically limited effective treatment options.
  • An early-stage finding (preclinical or early human) that already shows at least one concrete signal of significance above.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: NSCLC patients (exact eligibility/staging not specified by the frozen source). (Unspecified)

This is a trial-status story, not a results story. Multiple monotherapy/combination cohorts exist per the registry and must not be collapsed into a single universal regimen in any summary. No efficacy claim is supported — the story must remain "ongoing trial / investigational vaccine," never "lung cancer vaccine works." Registry status (recruiting, enrollment count, last-update date) is time-sensitive and should be re-checked before publication, not assumed static.

Full evidence details
Study design
Non-randomized trial
Sample size
320

Funding & Conflicts

Sponsor: BioNTech SE (as reported via the source-verification pass).

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-11

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-11

Primary evidence supporting this story

Why Should I Trust This?

  • Last reviewed: 2026-08-11

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

BNT116 lung-cancer vaccine remains under study in first-in-human trial

https://cancerdiscoveries.com/discoveries/bnt116-lung-cancer-vaccine-remains-under-study-in-first-in-human-trial/

Evidence stage: Early Human

What This Means

An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities, treatment-emergent adverse events) and dose.

What This Doesn't Mean

This is not evidence the vaccine works — no primary efficacy result exists to report, and no study results have been posted to the registry; any preliminary efficacy signal in this trial is secondary/exploratory only.

Why It Matters

Represents continued investment in therapeutic cancer vaccines for one of the most common and lethal cancers; worth tracking as the trial progresses.

Primary sources

  • LuCa-MERIT-1 trial registry (BNT116) — https://clinicaltrials.gov/study/NCT05142189 (NCT05142189)

Date verified: 2026-08-11

Correction status: No correction or retraction